Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Hindson Benjamin J.	2. Issuer Name and Ticker or Trading Symbol 10x Genomics, Inc. [ TXG ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) See Remarks
(Last) (First) (Middle) C/O 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD	3. Date of Earliest Transaction (MM/DD/YYYY) 11/1/2021
(Street) PLEASANTON, CA 94588 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	11/1/2021		M⁽¹⁾		10232	A	$5.04	57349	D
Class A Common Stock	11/1/2021		M⁽¹⁾		31434	A	$11.48	88783	D
Class A Common Stock	11/1/2021		S⁽¹⁾		1100	D	$160.5036 ⁽²⁾	87683	D
Class A Common Stock	11/1/2021		S⁽¹⁾		1500	D	$162.0606 ⁽³⁾	86183	D
Class A Common Stock	11/1/2021		S⁽¹⁾		11829	D	$163.1541 ⁽⁴⁾	74354	D
Class A Common Stock	11/1/2021		S⁽¹⁾		24125	D	$163.8672 ⁽⁵⁾	50229	D
Class A Common Stock	11/1/2021		S⁽¹⁾		3112	D	$164.7514 ⁽⁶⁾	47117	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$5.04	11/1/2021		M ⁽¹⁾			10232	⁽⁷⁾	11/2/2028	Class A Common Stock	10232	$0.00	50884	D
Stock Option (right to buy)	$11.48	11/1/2021		M ⁽¹⁾			31434	⁽⁸⁾	5/10/2029	Class A Common Stock	31434	$0.00	68566	D

Explanation of Responses:
(1)	The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
(2)	This transaction was executed in multiple trades at prices ranging from $160.00 to $160.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
(3)	This transaction was executed in multiple trades at prices ranging from $161.45 to $162.43. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
(4)	This transaction was executed in multiple trades at prices ranging from $162.48 to $163.475. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
(5)	This transaction was executed in multiple trades at prices ranging from $163.48 to $164.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
(6)	This transaction was executed in multiple trades at prices ranging from $164.50 to $165.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
(7)	This option, originally for 175,000 shares, of which 124,116 shares have been exercised, vested as to 1/48th of the shares on October 1, 2018 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
(8)	This option, originally for 100,000 shares, of which 31,434 shares have been exercised, vested as to 1/48th of the shares on May 1, 2019 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Remarks:
Chief Scientific Officer and President

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Hindson Benjamin J. C/O 10X GENOMICS, INC. 6230 STONERIDGE MALL ROAD PLEASANTON, CA 94588	X		See Remarks